Sumitomo Dainippon Pharma will acquire at least 10% of Roivant in addition to its interest in five pharmaceutical subsidiaries through the deal.

Pharmaceutical firm Sumitomo Dainippon Pharma is set to take a stake of at least 10% in US-based pharmaceutical and health technology company builder Roivant Sciences as part of a $3bn investment agreed yesterday. Roivant’s business model involves the formation of a series of subsidiaries it calls ‘vants’, each of which concentrate on a separate disease…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.